Holen Sie sich die Stockscreener-App
73.77
0.20%
0.15
Handel nachbörslich:
73.77
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt CYTK?
Forum
Prognose
Aktiensplit
Cytokinetics Inc Aktie (CYTK) Neueste Nachrichten
Cytokinetics Inc (CYTK) Director Robert Landry Sells 1,000 Shares - GuruFocus
Cytokinetics director Robert Landry sells $74,660 in shares By Investing.com - Investing.com South Africa
Cytokinetics director Robert Landry sells $74,660 in shares - Investing.com
Cytokinetics (NASDAQ: CYTK) director plans 2,000-share Rule 144 sale - Stock Titan
If You Invested $1000 In Cytokinetics Stock 10 Years Ago, You Would Have This Much Today - Benzinga
Cantor Fitzgerald reiterates Overweight on Cytokinetics stock By Investing.com - Investing.com Australia
Cytokinetics Has Advantage in Bristol-Myers Squibb Patent Dispute, RBC Says - marketscreener.com
Cytokinetics at citigroup summit: hcm expansion drives growth hopes By Investing.com - Investing.com Nigeria
Transcript : Cytokinetics, Incorporated Presents at Citigroup?s Biopharma Back to School Summit 2026, Sep-09-2026 03 - marketscreener.com
Cytokinetics at citigroup summit: hcm expansion drives growth hopes - investing.com
Cytokinetics (CYTK) Insider Sell: EVP Research & Development Fad - GuruFocus
Could Aficamten Give Cytokinetics the First Approved nHCM Treatment? - Yahoo Finance
Cytokinetics, Inc. (CYTK) Stock Analysis: Biotech Growth With 51% Upside Potential - DirectorsTalk Interviews
Will Camzyos' Long-Term Benefits Strengthen BMY's Growth Outlook? - Zacks Investment Research
Cytokinetics to Participate in September Investor Conferences - marketscreener.com
Can CYTK's Aficamten Strengthen Its HCM Growth Prospects? - Eastern Progress
Director B Parshall Sells 5,000 Shares of Cytokinetics Inc (CYTK) - GuruFocus
Cytokinetics Insider Sold Shares Worth $357,400, According to a Recent SEC Filing - marketscreener.com
Cytokinetics (NASDAQ: CYTK) director sale under 10b5-1 plan - Stock Titan
Cytokinetics (NASDAQ: CYTK) director moves to sell 5,000 vested shares - Stock Titan
Truist Financial Maintains Cytokinetics(CYTK.US) With Buy Rating, Maintains Target Price $112 - Moomoo
Cytokinetics (CYTK) Presents New Phase 3 Data, Is It Still 34% Undervalued? - Yahoo Finance
Truist reiterates Buy on Cytokinetics stock, $112 target on HCM potential - Investing.com
Truist reiterates Buy on Cytokinetics stock, $112 target on HCM potential By Investing.com - Investing.com Canada
Cytokinetics (CYTK) Reaches A Phase 3 First In Non Obstructive HCM - Yahoo Finance
CYTK5615147 Bond Profile — Key Metrics - TradingView
Cytokinetics (CYTK) CEO exercises options, sells 7,500 shares - Stock Titan
What's Going On With Cytokinetics Stock Today?Cytokinetics (NASDAQ:CYTK) - Benzinga
ESC ‘26: Cytokinetics’ sell-off, Arrowhead’s edge and a heart drug autopsy - BioPharma Dive
Cytokinetics, Inc. (CYTK) Stock Analysis: A Biotech Powerhouse with 52.45% Upside Potential - DirectorsTalk Interviews
Cytokinetics (CYTK) Is Down 6.2% After Positive Phase 3 Aficamten Data In Non-Obstructive HCMHas The Bull Case Changed? - webull.com
Cytokinetics Announces Additional ACACIA-HCM and MAPLE-HCM Results Showing Aficamten Benefits Across Hypertrophic Cardiomyopathy Spectrum - Quiver Quantitative
Cytokinetics Announces Additional Results from ACACIA-HCM and MAPLE-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology (ESC) Congress 2026 - Yahoo Finance
ESC: Cytokinetics Confirms Strong Case For Myqorzo Label Expansion - insights.citeline.com
If You Invested $100 In Cytokinetics Stock 10 Years Ago, You Would Have This Much Today - Benzinga
Why Cytokinetics (CYTK) Stock Is Down Today - Quiver Quantitative
Cytokinetics details trial win for what could be its next approval - STAT
Cytokinetics Announces Positive Phase 3 ACACIA-HCM Results for Aficamten in Non-Obstructive Hypertrophic Cardiomyopathy - Quiver Quantitative
Cytokinetics' aficamten showed gains in patient scores and exercise in Phase 3 trial - Stock Titan
Cytokinetics (CYTK) Institutional Ownership 2026 $CYTK - MarketBeat
News on AstraZeneca, Cytokinetics, Novartis and more — what to look out for at ESC 2026 - Endpoints News
Cytokinetics, Incorporated (CYTK) Stock Analysis: Evaluating a Potential 43% Upside in the Biotech Sector - DirectorsTalk Interviews
Insider Transaction: Cytokinetics CEO Robert Blum Sells 7,500 Shares for $575,700 - Yahoo Finance
Cytokinetics succeeds where Bristol Myers failed in heart muscle disease - Endpoints News
Cytokinetics to Present ACACIA-HCM Hot Line Results and Host Investor Event at ESC Congress 2026 - Quiver Quantitative
Cytokinetics Announces Upcoming Presentations at the European Society of Cardiology (ESC) ... - Caledonian Record
Cytokinetics Announces Upcoming Presentations at the European Society of Cardiology (ESC) Congress 2026 - Yahoo Finance
CYTK Stock Jumped To Over 2-Year Highs On HCM Trial Outcome – So, Why Are Analysts Bullish On Edgewise Therapeutics? - Stocktwits
Cytokinetics Gains 20.5% YTD: Buy, Sell or Hold the Stock? - Eastern Progress
Cytokinetics (CYTK) EVP Research & Development Fady Malik Sells 3,500 Shares - GuruFocus
Cytokinetics EVP Fady Ibraham Exercises Stock Options and Sells 3,500 Shares Under Rule 10b5-1 Plan - Kalkine Media
Cytokinetics EVP research & development sells $265,370 in stock By Investing.com - Investing.com Nigeria
Cytokinetics EVP research & development sells $265,370 in stock - Investing.com
Insider Selling: Cytokinetics (NASDAQ:CYTK) EVP Sells $265,370.00 in Stock - MarketBeat
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
symbol__ Stock Quote Price and Forecast - CNN
0.24%
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):